Discover more
Generate evidence that payers demand and reveal your product value
Collaborate with industry-recognized experts who apply scientific methodologies to conduct global health economics and outcomes research (HEOR) analysis for effective strategic planning. Gain an assessment of the cost-effectiveness, budget impact, and overall value of your products in real-world settings.
We combine rigorous technical expertise with a deep understanding of local markets and various disease states to deliver relevant, transparent, and credible results.
- Generate evidence that payers demand and reveal your product value.
- Differentiate products and drive market access with health outcomes and economic evaluations of a disease state.
- Design credible, transparent, user-friendly models that payers trust while accurately and clearly communicating complex data.
Features and services
When the gold standard of head-to-head clinical trial data is limited or unavailable, manufacturers turn to Cencora for evidence synthesis through systematic review and meta-analysis. Applying more than two decades of experience in conducting literature reviews, developing dossiers, and performing complex statistical analyses in numerous therapeutic areas, we provide turnkey support.
Identify patient trends, understand complex disease states and methodologies, and communicate value via our deep knowledge of Food and Drug Administration requirements (Section 114) in the application and use of scientific evidence through a wide array of visually impactful, easy-to-use tools. Using enhanced graphics, navigation, and macros, you can showcase multiple data endpoints including cost-effectiveness, budget impact, or burden of disease.
Rely on Cencora to bring clarity to an unclear treatment landscape, identify gaps in evidence generation or knowledge in the public domain, or provide the rigorous evidentiary support necessary for health technology assessments or publications. We stay current on tools and methodologies that can help you take a step further, and conduct feasibility assessments, statistical recommendations, and quantitative analyses.
In a marketplace that increasingly demands more comparative evidence of high-cost treatments, health outcomes and economic evaluations of a disease state can help differentiate products and drive market access. Our quality improvement programs encompass a broad spectrum, from traditional partnerships that include educational programs and interventions to advanced outcome performance measurement. These initiatives provide value to manufacturers, payers, providers, and patients by increasing access to care.
We have extensive experience building budget impact analyses (BIAs) for complex specialty products, including rare disease, oncology and immunology (including biosimilar) products; as well as medical device and diagnostics. Our BIA models are developed within established guidelines of individual public and private payers, and articulate the incremental budget impact to the payer’s bottom line.
